Robotic surgery arms race heats up as margins squeezed

In 2013, joint replacement procedures were still commonly performed using manual instrumentation rather than robotic platforms: surgeons relied on manual alignment guides, cutting blocks, and saws, with execution shaped by preoperative imaging and intraoperative judgment. That conventional workflow was the standard practice until robotic systems began addressing variability in positioning and alignment around 2013, making the period less a mature robotics era than a late-manual phase in which the limits of traditional alignment and positioning methods were becoming more visible.

The clearest inflection point came on December 17, 2013, when Stryker completed its acquisition of MAKO Surgical for approximately $1.65 billion, turning a broader technological shift into a concrete strategic move inside joint reconstruction. By integrating MAKO's robotic arm system and implant applications into its joint-reconstruction product line, Stryker linked its future in the category to robotic-assisted platforms, marking a decisive break from the manual-tool workflow that had still defined most procedures earlier that year.

The late-October robotics updates matter because they sharpen the case that technology is being used as a margin-defense strategy, not just a product story. Simply Wall Street says investors must believe Zimmer Biomet’s push into robotics and digital surgery can offset pricing pressure, higher manufacturing costs and near-term margin strain, while also noting the company is “managing an 80 basis point pricing headwind and planned operating margin pressure in 2026” and warning that “Zimmer Biomet’s story can break if pricing pressure near 80 basis points and the recent margin declines deepen rather than ease as projects ramp up.”

That is why the India launch of ROSA Knee and the first ROSA Shoulder procedures landed as commercially important proof points: they show the platforms moving into new geographies and more complex use cases where surgeon uptake can translate into share gains. Simply Wall Street said “Robotics headlines and a 30 day gain of 8.45% feed the bullish story,” even though “the 1 year total shareholder return has declined 3.31% and the 5 year total shareholder return is down 25.80%,” underscoring that investors are rewarding evidence that robotic platforms, digital planning and partnerships can drive adoption at scale despite broader pressure.

Robotics is being deployed less as a gadget than as a franchise defense: Stryker said, “Mako Their robotics platform just turned 20 years old and they had their best ever second quarter for Mako installations… Over 2.5 million procedures done globally now, systems in 47 countries.” That scale matters because it turns implants, software and capital equipment into a bundled offering hospitals and surgeons are less likely to swap out on price alone; as one Stryker executive put it, MAKO “took 20% of the market in partial knees in four years,” and they “interviewed surgeons who loved Mako.”

The margin-defense logic also shows up in how manufacturers finance and extend these platforms. A Stryker executive said the original robotics deal was “asymmetric upside… we had such financial strength we could afford to be wrong,” with downside capped at having “written off a billion dollars of the 1.6 billion,” while Medtronic is broadening Hugo by adding familiar tools, “especially as surgeons already know LigaSure from millions of prior cases,” and leveraging “Its US$118.7 billion scale in medical equipment gives it a broad installed base, where new tools on the Hugo robotic system can plug into” existing workflows; Zimmer Biomet’s multi-year Think Surgical extension shows partnerships can widen that moat without building every capability alone.